These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 27110122)

  • 21. Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma.
    Palumbo C; Benvenuto M; Focaccetti C; Albonici L; Cifaldi L; Rufini A; Nardozi D; Angiolini V; Bei A; Masuelli L; Bei R
    Front Med (Lausanne); 2023; 10():1066021. PubMed ID: 36817764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Taberna M; Oliva M; Mesía R
    Front Oncol; 2019; 9():383. PubMed ID: 31165040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients.
    Bei R; Budillon A; Masuelli L; Cereda V; Vitolo D; Di Gennaro E; Ripavecchia V; Palumbo C; Ionna F; Losito S; Modesti A; Kraus MH; Muraro R
    J Pathol; 2004 Nov; 204(3):317-25. PubMed ID: 15476268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Role of Dacomitinib in Head and Neck Cancer.
    Elicin O; Ozsahin M
    Expert Opin Investig Drugs; 2016 Jun; 25(6):735-42. PubMed ID: 27070370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting ErbB receptors in high-grade glioma.
    Berezowska S; Schlegel J
    Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Sacco AG; Cohen EE
    J Clin Oncol; 2015 Oct; 33(29):3305-13. PubMed ID: 26351341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
    Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
    Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
    De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
    Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
    Azoury SC; Gilmore RC; Shukla V
    Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands.
    O-charoenrat P; Rhys-Evans P; Court WJ; Box GM; Eccles SA
    Clin Exp Metastasis; 1999; 17(7):631-9. PubMed ID: 10845563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Patel B; Saba NF
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
    Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
    Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.
    Leonard B; Brand TM; O'Keefe RA; Lee ED; Zeng Y; Kemmer JD; Li H; Grandis JR; Bhola NE
    Cancer Res; 2018 Aug; 78(15):4331-4343. PubMed ID: 29792310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
    Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies.
    Pollock NI; Wang L; Wallweber G; Gooding WE; Huang W; Chenna A; Winslow J; Sen M; DeGrave KA; Li H; Zeng Y; Grandis JR
    Clin Cancer Res; 2015 Oct; 21(20):4597-606. PubMed ID: 26138066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-treatment of wild-type EGFR head and neck cancer cell lines with afatinib and cisplatin.
    Brands RC; Müller-Richter UD; De Donno F; Seher A; Mutzbauer G; Linz C; Kübler AC; Hartmann S
    Mol Med Rep; 2016 Mar; 13(3):2338-44. PubMed ID: 26782932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
    Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
    Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.